{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:24:04Z","timestamp":1782411844140,"version":"3.54.5"},"reference-count":36,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province, China","doi-asserted-by":"publisher","award":["2020J011213"],"award-info":[{"award-number":["2020J011213"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Pan-cancer analysis is an efficient tool to obtain a panoramic view of cancer-\nrelated genes and identify their oncogenic processes, facilitating the development of new therapeutic\ntargets. Lysine methyltransferase 2D (KMT2D), acting as a major enhancer coactivator for\nmammalian cells, is one of the most frequently mutated genes across various cancer types and is\nconsidered an oncogene and a rationale for epigenetic therapeutic targets.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study was designed to explore the potential role of KMT2D in human cancer\nthrough a pan-cancer analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The expression of KMT2D was assessed in normal tissues and cell lines, and pancancers\nfrom The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), and\nGenotype-Tissue Expression (GTE) datasets were used to explore its correlation with prognosis,\nimmune cell infiltration, tumor mutation burden, microsatellite instability, and mismatch repair.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>KMT2D expression was heterogeneous across different cancer types. Increased KMT2D\nindicated a worse prognosis in adrenocortical carcinoma (ACC), brain lower-grade glioma (LGG),\nand mesothelioma (MESO), while patients with high KMT2D expression showed better outcomes\nin renal clear cell carcinoma (KIRC). Moreover, KMT2D expression was positively correlated with\nimmune cell infiltration and negative tumor mutation burden in multiple cancers. In addition, a\nsignificant correlation between KMT2D and immune checkpoint-related genes or mismatch repair\ngenes was identified.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>These findings support the hypothesis that KMT2D is not only a potential biomarker\nfor prognosis and immunotherapy response prediction but also an essential immune regulator in\nhuman cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1386207325666220221092318","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T04:30:59Z","timestamp":1645504259000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pan-Cancer Analysis of Histone Methyltransferase KMT2D with Potential\nImplications for Prognosis and Immunotherapy in Human Cancer"],"prefix":"10.2174","volume":"26","author":[{"given":"Guangcheng","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Urology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoning","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","year":"2012","unstructured":"IARC, W. GLOBOCAN 2012: Estimated cancer incidence, mortality\nand prevalence worldwide in 2012. Globocan, 2012"},{"key":"ref=2","first-page":"pp.66","author":"Tarver T.","year":"2012","unstructured":"Tarver T.; Cancer facts & figures 2012; American Cancer Society\n(ACS) Atlanta: Atlanta, GA, 2012,pp.66"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"Underwood T.","year":"2020","unstructured":"Underwood T.; ICGC\/TCGA Pan-cancer analysis of whole genomes consortium. Pan-cancer analysis of whole genomes. Nature 2020,578(7793),82-93","journal-title":"Nature"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"578345","DOI":"10.3389\/fgene.2020.578345","volume":"11","author":"Das T.","year":"2020","unstructured":"Das T.; Andrieux G.; Ahmed M.; Chakraborty S.; Integration of online omics-data resources for cancer research. Front Genet 2020,11,578345","journal-title":"Front Genet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13148-019-0802-2","volume":"12","author":"Lavery W.J.","year":"2020","unstructured":"Lavery W.J.; Barski A.; Wiley S.; Schorry E.K.; Lindsley A.W.; KMT2C\/D COMPASS complex-associated diseases [KCDCOM-ADs]: An emerging class of congenital regulopathies. Clin Epigenetics 2020,12(1),10","journal-title":"Clin Epigenetics"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.molcel.2013.01.038","volume":"49","author":"Calo E.","year":"2013","unstructured":"Calo E.; Wysocka J.; Modification of enhancer chromatin: What, how, and why? Mol Cell 2013,49(5),825-837","journal-title":"Mol Cell"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.gene.2017.06.056","volume":"627","author":"Froimchuk E.","year":"2017","unstructured":"Froimchuk E.; Jang Y.; Ge K.; Histone H3 lysine 4 methyltransferase KMT2D. Gene 2017,627,337-342","journal-title":"Gene"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/24190","volume":"396","author":"Ait-Si-Ali S.","year":"1998","unstructured":"Ait-Si-Ali S.; Ramirez S.; Barre F.X.; Dkhissi F.; Magnaghi-Jaulin L.; Girault J.A.; Robin P.; Knibiehler M.; Pritchard L.L.; Du-commun B.; Trouche D.; Harel-Bellan A.; Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and onco-protein E1A. Nature 1998,396(6707),184-186","journal-title":"Nature"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"Gao J.","year":"2013","unstructured":"Gao J.; Aksoy B.A.; Dogrusoz U.; Dresdner G.; Gross B.; Sumer S.O.; Sun Y.; Jacobsen A.; Sinha R.; Larsson E.; Cerami E.; Sand-er C.; Schultz N.; Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013,6(269),pl1-pl1","journal-title":"Sci Signal"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2020.03.005","volume":"37","author":"Alam H.","year":"2020","unstructured":"Alam H.; Tang M.; Maitituoheti M.; Dhar S.S.; Kumar M.; Han C.Y.; Ambati C.R.; Amin S.B.; Gu B.; Chen T-Y.; KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer. Cancer Cell 2020,37(4),599-617","journal-title":"Cancer Cell"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1126\/science.aah6893","volume":"355","author":"Toska E.","year":"2017","unstructured":"Toska E.; Osmanbeyoglu H.U.; Castel P.; Chan C.; Hendrickson R.C.; Elkabets M.; Dickler M.N.; Scaltriti M.; Leslie C.S.; Arm-strong S.A.; Baselga J.; PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science 2017,355(6331),1324-1330","journal-title":"Science"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/onc.2009.416","volume":"29","author":"Pag&#xE8;s F.","year":"2010","unstructured":"Pag&#xE8;s F.; Galon J.; Dieu-Nosjean M.C.; Tartour E.; Saut&#xE8;s-Fridman C.; Fridman W.H.; Immune infiltration in human tumors: A prog-nostic factor that should not be ignored. Oncogene 2010,29(8),1093-1102","journal-title":"Oncogene"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.7150\/jca.35901","volume":"10","author":"Zhang S-C.","year":"2019","unstructured":"Zhang S-C.; Hu Z-Q.; Long J-H.; Zhu G-M.; Wang Y.; Jia Y.; Zhou J.; Ouyang Y.; Zeng Z.; Clinical implications of tumor-infiltrating immune cells in breast cancer. J Cancer 2019,10(24),6175-6184","journal-title":"J Cancer"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","volume":"25","author":"Klempner S.J.","year":"2020","unstructured":"Klempner S.J.; Fabrizio D.; Bane S.; Reinhart M.; Peoples T.; Ali S.M.; Sokol E.S.; Frampton G.; Schrock A.B.; Anhorn R.; Reddy P.; Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: A review of current evidence. Oncologist 2020,25(1),e147-e159","journal-title":"Oncologist"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"Weinstein J.N.","year":"2013","unstructured":"Weinstein J.N.; Collisson E.A.; Mills G.B.; Shaw K.; Ozenberger B.A.; Ellrott K.; Shmulevich I.; Sander C.; Stuart J.; Cancer genome atlas research network. Nat Genet 2013,45(10),1113-1120","journal-title":"Nat Genet"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"Hoadley K.A.","year":"2018","unstructured":"Hoadley K.A.; Yau C.; Hinoue T.; Wolf D.M.; Lazar A.J.; Drill E.; Shen R.; Taylor A.M.; Cherniack A.D.; Thorsson V.; Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 2018,173(2),291-304","journal-title":"Cell"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cell.2018.03.033","volume":"173","author":"Ding L.","year":"2018","unstructured":"Ding L.; Bailey M.H.; Porta-Pardo E.; Thorsson V.; Colaprico A.; Bertrand D.; Gibbs D.L.; Weerasinghe A.; Huang K-l.; Tokheim C.; Per-spective on oncogenic processes at the end of the beginning of cancer genomics. Cell 2018,173(2),305-320","journal-title":"Cell"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"Sanchez-Vega F.","year":"2019","unstructured":"Sanchez-Vega F.; Mina M.; Marra M.; Pathways, oncogenic signaling cancer, the atlas, genome. Cell 2019,173,321-337","journal-title":"Cell"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4103\/aja.aja_36_19","volume":"22","author":"Lv S-D.","year":"2020","unstructured":"Lv S-D.; Wang H-Y.; Yu X-P.; Zhai Q-L.; Wu Y-B.; Wei Q.; Huang W-H.; Integrative molecular characterization of Chinese prostate cancer specimens. Asian J Androl 2020,22(2),162-168","journal-title":"Asian J Androl"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41388-017-0026-x","volume":"37","author":"Lv S.","year":"2018","unstructured":"Lv S.; Ji L.; Chen B.; Liu S.; Lei C.; Liu X.; Qi X.; Wang Y.; Lai-Han Leung E.; Wang H.; Zhang L.; Yu X.; Liu Z.; Wei Q.; Lu L.; Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene 2018,37(10),1354-1368","journal-title":"Oncogene"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1080\/15592294.2019.1634985","volume":"14","author":"Lv S.","year":"2019","unstructured":"Lv S.; Wen H.; Shan X.; Li J.; Wu Y.; Yu X.; Huang W.; Wei Q.; Loss of KMT2D induces prostate cancer ROS-mediated DNA dam-age by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3. Epigenetics 2019,14(12),1194-1208","journal-title":"Epigenetics"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/nm.3943","volume":"21","author":"Ortega-Molina A.","year":"2015","unstructured":"Ortega-Molina A.; Boss I.W.; Canela A.; Pan H.; Jiang Y.; Zhao C.; Jiang M.; Hu D.; Agirre X.; Niesvizky I.; Lee J.E.; Chen H.T.; Ennishi D.; Scott D.W.; Mottok A.; Hother C.; Liu S.; Cao X.J.; Tam W.; Shaknovich R.; Garcia B.A.; Gascoyne R.D.; Ge K.; Shilatifard A.; Elemento O.; Nussenzweig A.; Melnick A.M.; Wendel H.G.; The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med 2015,21(10),1199-1208","journal-title":"Nat Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"108924","DOI":"10.1016\/j.biopha.2019.108924","volume":"115","author":"Sun P.","year":"2019","unstructured":"Sun P.; Wu T.; Sun X.; Cui Z.; Zhang H.; Xia Q.; Zhang D.; KMT2D inhibits the growth and metastasis of bladder cancer cells by maintaining the tumor suppressor genes. Biomed Pharmacother 2019,115,108924","journal-title":"Biomed Pharmacother"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/gutjnl-2017-315690","volume":"68","author":"Koutsioumpa M.","year":"2019","unstructured":"Koutsioumpa M.; Hatziapostolou M.; Polytarchou C.; Tolosa E.J.; Almada L.L.; Mahurkar-Joshi S.; Williams J.; Tirado-Rodriguez A.B.; Huerta-Yepez S.; Karavias D.; Kourea H.; Poultsides G.A.; Struhl K.; Dawson D.W.; Donahue T.R.; Fern&#xE1;ndez-Zapico M.E.; Iliopoulos D.; Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming. Gut 2019,68(7),1271-1286","journal-title":"Gut"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1158\/0008-5472.CAN-16-0481","volume":"76","author":"Dawkins J.B.","year":"2016","unstructured":"Dawkins J.B.; Wang J.; Maniati E.; Heward J.A.; Koniali L.; Kocher H.M.; Martin S.A.; Chelala C.; Balkwill F.R.; Fitzgibbon J.; Grose R.P.; Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic duc-tal adenocarcinoma. Cancer Res 2016,76(16),4861-4871","journal-title":"Cancer Res"},{"key":"ref=26","first-page":"2, e01503","author":"Lee J-E","year":"2013","unstructured":"Lee J-E; Wang C; Xu S; Cho Y-W; Wang L; Feng X; Baldridge A; Sartorelli V; Zhuang L; Peng W; H3K4 mono-and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. elife 2013,2, e01503"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.molcel.2017.04.018","volume":"66","author":"Dorighi K.M.","year":"2017","unstructured":"Dorighi K.M.; Swigut T.; Henriques T.; Bhanu N.V.; Scruggs B.S.; Nady N.; Still C.D.; Garcia B.A.; Adelman K.; Wysocka J.; Mll3 and Mll4 facilitate enhancer RNA synthesis and transcription from promoters independently of H3K4 monomethylation. Molecular cell 2017,66(4),568-576","journal-title":"Molecular cell"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMc1903064","volume":"380","author":"Esfahani K.","year":"2019","unstructured":"Esfahani K.; Buhlaiga N.; Th&#xE9;bault P.; Lapointe R.; Johnson N.A.; Miller W.H.; Jr Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med 2019,380(24),2375-2376","journal-title":"N Engl J Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y.; Zhang Z.; The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 2020,17(8),807-821","journal-title":"Cell Mol Immunol"},{"key":"ref=30","first-page":"135","volume":"194","author":"Placek K.","year":"2015","unstructured":"Placek K.; Cui K.; Hu G.; Lee J-E.; Wang C.; Konkel J.; Zhang D.; Chen W.; Ge K.; Zhao K.; KMT2D histone methyltransferase modulates chromatin accessibility during regulatory T cell development (LYM6P. 714). Am Assoc Immnol 2015,194(1),135","journal-title":"Am Assoc Immnol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"20492","DOI":"10.1038\/s41598-021-99724-9","volume":"11","author":"Chen D.","year":"2021","unstructured":"Chen D.; Jin C.; Dong X.; Wen J.; Xia E.; Wang Q.; Wang O.; Pan-cancer analysis of the prognostic and immunological role of PSMB8. Sci Rep 2021,11(1),20492","journal-title":"Sci Rep"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"5551036","DOI":"10.1155\/2021\/5551036","volume":"2021","author":"Chen F.","year":"2021","unstructured":"Chen F.; Fan Y.; Cao P.; Liu B.; Hou J.; Zhang B.; Tan K.; Pan-cancer analysis of the prognostic and immunological role of HSF1: A po-tential target for survival and immunotherapy. Oxid Med Cell Longev 2021,2021,5551036","journal-title":"Oxid Med Cell Longev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"646523","DOI":"10.3389\/fimmu.2021.646523","volume":"12","author":"Cheng X.","year":"2021","unstructured":"Cheng X.; Wang X.; Nie K.; Cheng L.; Zhang Z.; Hu Y.; Peng W.; Systematic pan-cancer analysis identifies TREM2 as an immunologi-cal and prognostic biomarker. Front Immunol 2021,12,646523","journal-title":"Front Immunol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1158\/2159-8290.CD-19-1448","volume":"10","author":"Wang G.","year":"2020","unstructured":"Wang G.; Chow R.D.; Zhu L.; Bai Z.; Ye L.; Zhang F.; Renauer P.A.; Dong M.B.; Dai X.; Zhang X.; Du Y.; Cheng Y.; Niu L.; Chu Z.; Kim K.; Liao C.; Clark P.; Errami Y.; Chen S.; CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. Cancer Discov 2020,10(12),1912-1933","journal-title":"Cancer Discov"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1101\/gad.275453.115","volume":"30","author":"Kantidakis T.","year":"2016","unstructured":"Kantidakis T.; Saponaro M.; Mitter R.; Horswell S.; Kranz A.; Boeing S.; Ayg&#xFC;n O.; Kelly G.P.; Matthews N.; Stewart A.; Stewart A.F.; Svejstrup J.Q.; Mutation of cancer driver MLL2 results in transcription stress and genome instability. Genes Dev 2016,30(4),408-420","journal-title":"Genes Dev"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"Ray Chaudhuri A.","year":"2016","unstructured":"Ray Chaudhuri A.; Callen E.; Ding X.; Gogola E.; Duarte A.A.; Lee J-E.; Wong N.; Lafarga V.; Calvo J.A.; Panzarino N.J.; John S.; Day A.; Crespo A.V.; Shen B.; Starnes L.M.; de Ruiter J.R.; Daniel J.A.; Konstantinopoulos P.A.; Cortez D.; Cantor S.B.; Fernandez-Capetillo O.; Ge K.; Jonkers J.; Rottenberg S.; Sharan S.K.; Nussenzweig A.; Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 2016,535(7612),382-387","journal-title":"Nature"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1386207325666220221092318","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/201295\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1386207325666220221092318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T12:59:49Z","timestamp":1677848389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/201295\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207325666220221092318","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}